常染色体显性多囊肾病患者的腹膜透析结局
该回顾性队列基于美国肾脏数据系统2000至2021年53,651例新发ESKD的ADPKD患者,26%接受过腹膜透析。校正混杂因素后,腹膜透析与较低死亡风险(HR 0.84)和较高肾移植可能性(HR 1.12)相关,且随时间推移关联更显著。
要点
- 腹膜透析可成功用于ADPKD患者,且与较低死亡风险相关(HR 0.84)。
- 腹膜透析与较高肾移植可能性相关(HR 1.12)。
- 腹膜透析的生存与移植优势随时间推移逐渐增强。
核心结论
- 腹膜透析是ADPKD患者安全且有利的透析选择,与更长患者生存和肾移植机会相关。
研究设计与样本
- 回顾性队列纳入美国肾脏数据系统2000年1月1日至2021年12月31日注册的30岁及以上、诊断为囊性肾病的新发ESKD患者,随访至死亡或2023年1月1日。
主要发现
- 在53,651例新发ADPKD的ESKD患者中,26%接受过腹膜透析,中位随访75个月,26,375例(49%)接受肾移植,23,427例(44%)死亡。
- 校正年龄、性别、种族、BMI、血清白蛋白、血红蛋白、ESKD年份、保险状态和合并症后,腹膜透析与较低死亡率相关(HR 0.84;95% CI 0.80-0.88;P<0.001)。
- 校正后腹膜透析与较高肾移植可能性相关(HR 1.12;95% CI 1.08-1.16;P<0.001)。
- 腹膜透析与较低死亡率和较高移植的关联随年份推移逐渐更显著。
临床怎么用
- 临床可考虑将腹膜透析作为ADPKD合并ESKD患者的可行透析方式。
- 向ADPKD患者推荐腹膜透析时,可参考其与较低死亡风险和较高肾移植机会的关联。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Peritoneal dialysis can be used successfully in patients with autosomal dominant polycystic kidney disease. Compared with days receiving hemodialysis, peritoneal dialysis days were associated with better patient survival, which has increased over time. Compared with hemodialysis days, peritoneal dialysis days were associated with a higher rate of kidney transplant, which has increased over time. BACKGROUND: Peritoneal dialysis (PD) is a form of home dialysis that is underutilized in the United States. Patients with autosomal dominant polycystic kidney disease (ADPKD) are frequently good PD candidates who are often young and have few comorbid conditions. However, clinicians may be hesitant to recommend PD to patients with ADPKD because of perceived concerns for mechanical complications and technique failure. Little is known about outcomes of patients with ADPKD undergoing PD in the United States. METHODS: A retrospective cohort of patients with ESKD 30 years and older registered in the United States Renal Data System with a diagnosis of cystic kidney disease from January 1, 2000, to December 31, 2021, was followed until death or January 1, 2023, whichever occurred first. A time-dependent variable for kidney treatment modality was created, allowing calculation of hazard ratios (HRs) and confidence intervals (CIs) on the basis of time proximity of PD exposure to death and kidney transplantation, compared with hemodialysis. Cox models were adjusted for age, sex, race, body mass index, serum albumin, hemoglobin, year of incident ESKD, insurance status, and comorbid conditions at the time of inclusion. RESULTS: Among 53,651 incident ADPKD patients with ESKD, 26% received some PD. Over a median follow-up of 75 months, 26,375 (49%) of the patients received kidney transplants and 23,427 (44%) died. PD exposure was more likely among patients with ADPKD who were younger, were female, and had lower burden of comorbid diseases. In the adjusted models, PD was associated with lower mortality (HR, 0.84; 95% CI, 0.80 to 0.88, P < 0.001) and higher likelihood of transplant (HR, 1.12; 95% CI, 1.08 to 1.16; P < 0.001) compared with hemodialysis. The associations with lower mortality and higher transplantation became progressively more prominent with each passing year. CONCLUSIONS: These data indicate that PD is a safe and advantageous dialysis option for patients with ADPKD that is associated with longer patient survival and opportunities for kidney transplant.
引用
- Gunning S, McGill RL, Chapman AB, et al. Peritoneal Dialysis Outcomes in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2026. PMID: 42536420. doi:10.2215/CJN.0000001134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。